浩欧博(688656) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 was ¥88,334,621.36, representing a year-on-year increase of 35.78%[5] - The net profit attributable to shareholders for Q3 2021 was ¥29,675,291.60, reflecting a year-on-year growth of 51.28%[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2021 was ¥29,924,298.25, up 61.38% year-on-year[5] - Total revenue for the first three quarters of 2021 reached ¥235,876,946.48, a significant increase of 64% compared to ¥143,911,515.75 in the same period of 2020[22] - Operating profit for the first three quarters of 2021 was ¥86,395,501.55, up from ¥44,771,866.59 in the previous year, indicating a growth of 93%[23] - Net profit for the first three quarters of 2021 was ¥74,756,574.85, compared to ¥38,691,673.97 in 2020, representing an increase of 93%[23] - The total comprehensive income for the third quarter of 2021 was CNY 74,756,574.85, compared to CNY 38,727,693.91 in the same period of 2020, representing an increase of approximately 93%[24] Assets and Equity - The total assets at the end of the reporting period were ¥840,842,239.76, an increase of 183.68% compared to the end of the previous year[6] - The total equity attributable to shareholders at the end of the reporting period was ¥758,692,152.47, up 267.61% year-on-year[6] - Total assets as of September 30, 2021, amounted to ¥840,842,239.76, a substantial rise from ¥296,410,327.69 at the end of 2020[21] - The company's equity attributable to shareholders increased to ¥758,692,152.47 from ¥206,387,319.77, a growth of 267%[21] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥44,331,460.00, reflecting a year-on-year increase of 54.17%[6] - Cash flow from operating activities for the first nine months of 2021 was CNY 44,331,460.00, compared to CNY 28,755,128.93 in the same period of 2020, indicating a year-over-year increase of 54%[28] - Cash inflow from investment activities for the first nine months of 2021 was CNY 64,252,050.00, significantly higher than CNY 22,310,762.41 in the same period of 2020, marking an increase of 188%[28] - The net cash flow from financing activities for the first nine months of 2021 was CNY 456,587,826.08, compared to a net outflow of CNY 64,676,514.85 in the same period of 2020, showing a turnaround of CNY 521,264,340.93[29] Research and Development - Research and development expenses for Q3 2021 totaled ¥7,991,320.76, accounting for 9.05% of operating revenue, an increase of 0.08 percentage points year-on-year[6] - Research and development investment reached 7.99 million RMB in Q3 2021, a year-on-year increase of 36.95%[16] - Research and development expenses for the first three quarters of 2021 were ¥20,831,586.19, compared to ¥17,279,484.98 in the same period of 2020, an increase of 20%[22] Market Expansion and Operations - The company is actively expanding its domestic and international markets, with a focus on increasing marketing efforts and brand recognition[16] - The company has established new communication mechanisms with overseas agents to mitigate the impact of the COVID-19 pandemic on international marketing efforts[16] - The company experienced significant growth in performance due to the impact of the COVID-19 pandemic in the previous year[9] - The domestic market demand for the company's main products has recovered and grown, particularly in the sales of chemiluminescent products[14] Production and Capacity - The new factory in Hunan has expanded the company's production capacity and optimized product structure, enhancing competitiveness[14] - The company obtained 33 medical device registration certificates during the reporting period, including 26 new certificates for the automated allergy testing platform, Subok[14] Financial Stability - Total liabilities decreased to ¥82,150,087.29 from ¥90,023,007.92, showing a reduction of approximately 9%[20] - The company's cash and cash equivalents reached ¥146,239,656.14, up from ¥58,815,105.12, indicating a growth of 148%[18] - The total cash and cash equivalents at the end of the third quarter of 2021 amounted to CNY 146,239,656.14, up from CNY 42,781,352.91 at the end of the same quarter in 2020[29]